Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 20%Low 4 · 80%Moderate 0 · 0%High 0 · 0%

Cardiovascular adverse events

Silodosin showed no clear difference in cardiovascular adverse events compared with naftopidil (low certainty).

1 finding from 1 review

Cardiovascular adverse events

Silodosin showed no clear difference in cardiovascular adverse events compared with alfuzosin (low certainty).

1 finding from 1 review

Cardiovascular adverse events

It is very uncertain whether silodosin changes cardiovascular adverse events compared with placebo (very low certainty).

1 finding from 1 review

Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
RR 1.28 [0.67, 2.45]
4 studies · 1967 participants
Very low

Cardiovascular adverse events

Silodosin showed no clear difference in cardiovascular adverse events compared with tamsulosin (low certainty).

1 finding from 1 review

Cardiovascular adverse events

Naftopidil showed no clear difference in cardiovascular adverse events compared with silodosin (alpha‐blocker) (low certainty).

1 finding from 1 review